AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
10.97
+0.61 (5.89%)
At close: Aug 13, 2026, 4:00 PM EDT
10.96
-0.01 (-0.09%)
After-hours: Aug 13, 2026, 7:59 PM EDT
AbCellera Biologics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 120.07 | 128.51 | 156.33 | 133.32 | 386.54 | 476.14 |
Short-Term Investments | 420.04 | 405.31 | 469.29 | 627.27 | 499.95 | 246.84 |
Cash & Short-Term Investments | 540.1 | 533.83 | 625.61 | 760.59 | 886.49 | 722.98 |
Cash Growth | -2.35% | -14.67% | -17.75% | -14.20% | 22.62% | 21.69% |
Accounts Receivable | 18.6 | 58.29 | 33.62 | 30.59 | 38.59 | 160.58 |
Other Current Assets | 120.53 | 136.11 | 92.14 | 80.81 | 100.41 | 46.25 |
Total Current Assets | 679.23 | 728.23 | 751.37 | 871.99 | 1,025 | 929.8 |
Net Property, Plant & Equipment | 416.68 | 428 | 340.43 | 287.7 | 217.26 | 111.62 |
Other Intangible Assets | 36.53 | 38.38 | 42.11 | 120.43 | 131.5 | 148.39 |
Goodwill | 47.81 | 47.81 | 47.81 | 47.81 | 47.81 | 47.81 |
Long-Term Investments | 65.23 | 62.58 | 82.3 | 65.94 | 72.52 | 50.31 |
Other Long-Term Assets | 62.1 | 51.95 | 96.54 | 94.24 | 46.33 | 30.64 |
Total Assets | 1,308 | 1,357 | 1,361 | 1,488 | 1,541 | 1,319 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 32.48 | 50.78 | 55 | 49.58 | 52.5 | 32.02 |
Unearned Revenue | 20.71 | 13.53 | 13.52 | 18.96 | 21.61 | 7.54 |
Other Current Liabilities | - | - | 8.09 | 50.48 | 44.21 | 81.12 |
Total Current Liabilities | 53.19 | 64.31 | 76.61 | 119.01 | 118.32 | 120.68 |
Long-Term Leases | 129.95 | 137.4 | 60.74 | 71.22 | 76.68 | 36.41 |
Other Long-Term Liabilities | 228.42 | 188.34 | 167.11 | 145.54 | 112.64 | 135.75 |
Total Long-Term Liabilities | 358.37 | 325.74 | 227.86 | 216.76 | 189.31 | 172.16 |
Total Liabilities | 411.56 | 390.05 | 304.47 | 335.78 | 307.63 | 292.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 821.24 | 802.34 | 777.17 | 753.2 | 734.37 | 722.43 |
Additional Paid-in Capital | 206 | 198.28 | 166.36 | 121.05 | 74.12 | 35.36 |
Accumulated Other Comprehensive Income | -3.15 | -4.23 | -4.38 | -1.72 | -1.39 | 0.28 |
Retained Earnings | -128.07 | -29.48 | 116.93 | 279.79 | 426.19 | 267.67 |
Shareholders' Equity | 896.02 | 966.9 | 1,056 | 1,152 | 1,233 | 1,026 |
Total Liabilities & Equity | 1,308 | 1,357 | 1,361 | 1,488 | 1,541 | 1,319 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 129.95 | 137.4 | 60.74 | 71.22 | 76.68 | 36.41 |
Net Cash (Debt) | 410.16 | 396.42 | 564.87 | 689.36 | 809.81 | 686.56 |
Net Cash Growth | -1.38% | -29.82% | -18.06% | -14.87% | 17.95% | 16.29% |
Net Cash Per Share | 1.36 | 1.33 | 1.92 | 2.38 | 2.57 | 2.16 |
Book Value | 896.02 | 966.9 | 1,056 | 1,152 | 1,233 | 1,026 |
Book Value Per Share | 2.97 | 3.24 | 3.59 | 3.98 | 3.92 | 3.22 |
Tangible Book Value | 811.68 | 880.72 | 966.17 | 984.09 | 1,054 | 829.54 |
Tangible Book Value Per Share | 2.69 | 2.95 | 3.28 | 3.40 | 3.35 | 2.61 |